Volume 19, Number 10—October 2013
Clonal Distribution and Virulence of Campylobacter jejuni Isolates in Blood
Campylobacter jejuni bacteria are highly diverse enteropathogens. Seventy-three C. jejuni isolates from blood collected in Finland were analyzed by multilocus sequence typing and serum resistance. Approximately half of the isolates belonged to the otherwise uncommon sequence type 677 clonal complex. Isolates of this clonal complex were more resistant than other isolates to human serum.
The most common bacterial enteropathogen in industrialized countries is Campylobacter jejuni. This bacterium typically causes watery diarrhea with fever and abdominal pain (1,2). Complications, such as bacteremia, Guillain-Barré syndrome, and reactive arthritis, might also occur (3).
Multilocus sequence typing (MLST) has shown that C. jejuni is weakly clonal and highly diverse (4,5). Several MLST studies have identified particular niches for certain genetically related MLST lineages (6,7). Thus, MLST is robust in population genetics and source attribution studies.
Susceptibility to human serum varies between different species of Campylobacter; C. fetus is typically resistant, and C. jejuni is believed to be sensitive (8). Because serum resistance might contribute to spread of C. jejuni in the bloodstream, systemic isolates have been studied for their survival in human serum. However, numbers of isolates studied have been limited, and results compared with those for fecal isolates have not been distinctive (8,9).
In a recent nationwide study over a 10-year period, we collected blood culture isolates of C. jejuni and C. coli and obtained clinical features of corresponding bacteremic episodes and characteristics of patients throughout Finland (10). Our results showed that patients were moderately young and mostly without any underlying diseases (10). In the present study, we characterized C. jejuni blood culture isolates with respect to their clonal distribution and serum resistance.
The bacterial isolates were collected throughout Finland during 1998–2007 as described (10). Of 76 patients described, 3 were excluded because of C. coli infections. MLST was performed for 73 C. jejuni isolates as described (11). BioNumerics version 5.1 software (Applied Maths, Kortrijk, Belgium) was used for sequence assembly. Allele numbers, sequence types (STs), and clonal complexes (CCs) were assigned by using the PubMLST database (5). New alleles and STs were submitted to the database.
A serum sensitivity assay was conducted with 73 C. jejuni isolates according to a described protocol (8). The same pool of serum samples from 10 healthy blood donors was used in all experiments. C. jejuni NCTC 11168 and a C. fetus isolate from blood were used as control organisms.
All statistical analyses were performed by using Graphpad Prism version 4.03 (Graphpad Software, San Diego, CA, USA) and PASW Statistics version 18 (SPSS Inc., Chicago, IL, USA). The χ2 test and Fisher exact test were used for comparison of categorical variables. The Mann-Whitney test was used for the comparison of continuous variables. All tests were 2-sided, and p<0.05 was considered significant.
A total of 72 C. jejuni isolates from blood were successfully typed by MLST; 1 isolate had a mixed MLST pattern. Five isolates were in unassigned STs, and the rest were distributed among 11 CCs (Table). ST-677 CC was the predominant complex: 35 (48%) isolates. Genetic relatedness of these isolates was further confirmed by using pulsed-field gel electrophoresis.
Isolates belonging to ST-677 CC were obtained throughout the 10-year study period. However, bacteremia episodes caused by ST-677 CC isolates were exclusively diagnosed during the seasonal peak during May–August (Figure 1). Of C. jejuni blood culture isolates detected during May–August, most (64%) were ST-677 CC. Furthermore, ST-677 CC was the most prevalent complex in 4 geographic regions of Finland.
Susceptibility to human serum varied between C. jejuni isolates from different CCs (Figure 2). ST-677 CC isolates were significantly less susceptible to human serum than all other isolates (p<0.0001). ST-45 CC isolates were significantly more susceptible to human serum than all other isolates (p<0.0001).
We characterized a unique collection of 73 C. jejuni isolates from blood obtained during a nationwide study in Finland over a 10-year period. Despite the high population diversity of C. jejuni, nearly half of the isolates from blood showed clustering within the ST-677 CC, a rare CC in other countries (12,13). Furthermore, bacterial survival in human serum varied greatly. Thus, invasiveness of blood culture isolates could not be solely explained by their serum resistance, although the predominant isolates of ST-677 CC were more serum resistant than other isolates.
C. jejuni has high ST diversity. As of May 2, 2013, a total of 6,564 STs were registered (5). In this study, we detected clustering of C. jejuni isolates from blood in an uncommon ST-677 CC. Further studies are needed to clarify whether bacterial characteristics might explain this finding.
In our previous study, which included human fecal C. jejuni isolates obtained in Finland from the mid-1990s through 2007, which is nearly the same period as in the current nationwide study, 11.7% of the isolates belonged to ST-677 CC (11). The 2 most prevalent CCs in that study, ST-45 CC (43.6% of fecal isolates) and ST-21 CC (19.4% of fecal isolates), were detected only among 12 (16%) and 10 (14%) of blood culture isolates, respectively, in the present study.
ST-45 CC and ST-21 CC have been shown to be prevalent in several countries (4,13). However, our results suggest that these 2 CCs are not common among C. jejuni isolates from blood in Finland, which cluster more in the ST-677 CC. On the basis of the present results, we speculate that ST-677 CC might have a special invasive capability or has adapted to the environment in Finland.
In general, complement-mediated killing of serum-susceptible isolates plays a major role in restricting access of pathogens to the bloodstream. However, available information about possible serum sensitivity of C. jejuni isolates from blood is scarce (8,9). In our study of nonselected C. jejuni isolates from blood, susceptibility to human serum varied according to MLST CC.
In conclusion, in this nationwide study during a 10-year period in Finland, we found by MLST analysis that half of the bacteremia isolates of C. jejuni clustered within an otherwise uncommon ST-677 CC. Whether this finding indicates special adaptation of ST-677 CC to Finland or to the human bloodstream is not clear and needs to be studied. Our findings emphasize the role of using well-defined clinical materials in studies on bacterial pathogenicity and severity of human disease.
Dr Feodoroff is a clinician at Jorvi Hospital in Espoo, Finland. His primary research interest is severe Campylobacter infections in Finland.
We thank Anna Nilsson and Urzula Hirvi for skilled technical assistance. Results of this study have been presented as part of a doctoral thesis for B.F.
B.F. was supported by the Academy of Finland (Elvira grant to H.R), and C.P.A.dH. was supported by the Applied Bioscience Graduate School and the Academy of Finland (grant CoE MIFOSA 11411405 to M.-L.H.).
- Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis. 1997;176:S103–5 .
- European Food Safety Authority. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2009. January 21, 2012 [cited 2013 May 7]. http://www.efsa.europa.eu/de/efsajournal/pub/2090.htm.
- Blaser M, Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. In: Nachamkin I, Szymanski C, Blaser M, editors. Campylobacter, 3rd ed. Washington (DC): Amercian Society for Microbiology Press; 2008. p. 99–121.
- Dingle KE, Colles FM, Wareing DR, Ure R, Fox AJ, Bolton FE, Multilocus sequence typing system for Campylobacter jejuni. J Clin Microbiol. 2001;39:14–23.
- Campylobacter multi locus sequence typing website. May 2, 2013 [cited 2013 May 7]. http://pubmlst.org/campylobacter/.
- Sheppard SK, Colles FM, McCarthy ND, Strachan NJ, Ogden ID, Forbes KJ, Niche segregation and genetic structure of Campylobacter jejuni populations from wild and agricultural host species. Mol Ecol. 2011;20:3484–90.
- de Haan CP, Kivistö R, Hänninen ML. Association of Campylobacter jejuni Cj0859c Gene (fspA) variants with different C. jejuni multilocus sequence types. Appl Environ Microbiol. 2010a;76:6942–3.
- Blaser MJ, Smith PF, Kohler PF. Susceptibility of Campylobacter isolates to the bactericidal activity of human serum. J Infect Dis. 1985;151:227–35.
- Blaser MJ, Perez GP, Smith PF, Patton C, Tenover FC, Lastovica AJ, Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J Infect Dis. 1986;153:552–9.
- Feodoroff B, Lauhio A, Ellström P, Rautelin H. A nation-wide study of Campylobacter jejuni and C. coli bacteremia in Finland over a ten-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis. 2011;53:e99–106 .
- de Haan CP, Kivistö R, Hakkinen M, Rautelin H, Hänninen ML. Decreasing trend of overlapping multilocus sequence types between human and chicken Campylobacter jejuni isolates over a decade in Finland. Appl Environ Microbiol. 2010b;76:5228–36.
- Sheppard SK, Dallas JF, Strachan NJ, MacRae M, McCarthy ND, Wilson DJ, Campylobacter genotyping to determine the source of human infection. Clin Infect Dis. 2009;48:1072–8.
- Nielsen LN, Sheppard SK, McCarthy ND, Maiden MC, Ingmer H, Krogfelt KA. MLST clustering of Campylobacter jejuni isolates from patients with gastroenteritis, reactive arthritis and Guillain-Barré syndrome. J Appl Microbiol. 2010;108:591–9.
Suggested citation for this article: Feodoroff B, de Haan CPA, Ellström P, Sarna S, Hänninen M-L, Rautelin H. Clonal distribution and virulence of Campylobacter jejuni in blood. Emerg Infect Dis [Internet]. 2013 Oct [date cited]. http://dx.doi.org/10.3201/eid1910.121537
1Current affiliation: Jorvi Hospital, Espoo, Finland.
- Page created: September 16, 2013
- Page last updated: September 16, 2013
- Page last reviewed: September 16, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)